Naiera M. Helmy

Dr. Naiera M. Helmy

Microbial Biotechnology, National Research Centre, Cairo, Al Qāhirah, Egypt
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2025 in Pharmacological Reviews
Verified
Journal Article
Closed access
Cesar Augusto Roque-BordaCesar Augusto Roque-Borda
Cesar Augusto Roque-Borda
QZQi Zhang
Qi Zhang
TNThi Phuong Truc Nguyen
Thi Phuong Truc Nguyen
TNThi Thu Hoai Nguyen
Thi Thu Hoai Nguyen
HMHimadri Medhi
Himadri Medhi
Fernando Rogério PavanFernando Rogério Pavan
Fernando Rogério Pavan

19 October 2024 in Molecules
Verified
Journal Article
Open access
PDF file
NHNaiera M. Helmy
Naiera M. Helmy
Keykavous ParangKeykavous Parang
Keykavous Parang
Peptide-based inhibitors represent a promising approach for the treatment of HIV-1, offering a range of potential advantages, including specificity, low toxicity, and the ability to target various stages of the viral lifecycle. This review outlines the current state of research on peptide-based anti-HIV therapies, highlighting key advancements and identifying future research directions. Over the past few years, there has been significant progress in developing synthetic peptide-based drugs that target various stages of the viral life cycle, including entry and replication. These approaches aim to create effective anti-HIV therapies. Additionally, peptides have proven valuable in the development of anti-HIV vaccines. In the quest for effective HIV vaccines, discovering potent antigens and designing suitable vaccine strategies are crucial for overcoming challenges such as low immunogenicity, safety concerns, and increased viral load. Innovative strategies for vaccine development through peptide research are, therefore, a key focus area for achieving effective HIV prevention. This review aims to explore the strategies for designing peptides with anti-HIV activity and to highlight their role in advancing both therapeutic and preventive measures against HIV.

6 February 2023
Verified
Book Chapter
Open access
PDF file
REReem El-Shenawy
Reem El-Shenawy
SFSally Farouk
Sally Farouk
NHNaiera M. Helmy
Naiera M. Helmy
NDNoha Bader El Din
Noha Bader El Din
Hepatitis C virus (HCV) is the main etiology of advanced liver fibrosis and cirrhosis with significant risk of progression to hepatocellular carcinoma (HCC). Several epidemiologic studies have documented a lot of risk factors related to the progression of HCC in chronic HCV patients. Factors that increase the risk of HCC development include obesity, diabetes mellitus, nonalcoholic fatty liver disease, aflatoxin exposure, alcohol consumption, occult hepatitis C infection, and genetic variations. HCV patients with genotypes 3 and 1 are also more liable to develop HCC. Also, male gender and higher age are considered as independent risk factors for HCC. Using the newly discovered direct-acting antivirals (DAAs), great improvement in sustained virological immune response (SVR) has occurred 90% in treated patients irrespective of their fibrosis level. Nevertheless, the progression to HCC in HCV patients who achieve SVR stays vulnerable to HCC development, especially patients with advanced fibrosis and/or cirrhosis.

18 January 2024 in Microbial Cell Factories
Verified
Journal Article
Open access
PDF file
Heba ShawkyHeba Shawky
Heba Shawky
Ashraf TabllAshraf Tabll
Ashraf Tabll
REReem M. Elshenawy
Reem M. Elshenawy
NHNaiera M. Helmy
Naiera M. Helmy
RMRehab I. Moustafa
Rehab I. Moustafa
YEYasmine S. El-Abd
Yasmine S. El-Abd
Background: Although E. coli is generally a well-opted platform for the overproduction of recombinant antigens as heterologous proteins, the optimization of expression conditions to maximize the yield of functional proteins remains empirical. Herein, we developed an optimized E. coli (BL21)-based system for the overproduction of soluble immunoreactive HCV core/envelope proteins that were utilized to establish a novel immunoassay for discrimination of active HCV infection. Methods: The core/E1-E2 genes were amplified and expressed in E. coli BL21 (DE3) in the absence/presence of glycylglycine. The antigenic performance of soluble proteins was assessed against 63 HCV-seronegative (Ab−) sera that included normal and interferent sera (HBV and/or chronic renal failure), and 383 HCV-seropositive (Ab+) samples that included viremic (chronic/relapsers) and recovered patients’ sera. The color intensity (OD450) and S/Co values were estimated. Results: The integration of 0.1–0.4M glycylglycine in the growth media significantly enhanced the solubility/yield of recombinant core and envelope proteins by ~ 225 and 242 fold, respectively. This was reflected in their immunoreactivity and antigenic performance in the developed immunoassay, where the soluble core/E1/E2 antigen mixture showed 100% accuracy in identifying HCV viremic sera with a viral RNA load as low as 3800 IU/mL, without cross-reactivity against normal/interferent HCV-Ab−sera. The ideal S/Co threshold predicting active viremia (> 2.75) showed an AUC value of 0.9362 (95% CI: 0.9132 to 0.9593), with 87.64, 91.23% sensitivity and specificity, and 94.14, 82.11% positive and negative predictive values, respectively. The different panels of samples assayed with our EIA showed a good concordance with the viral loads and also significant correlations with the golden standards of HCV diagnosis in viremic patients. The performance of the EIA was not affected by the immunocompromised conditions or HBV co-infection. Conclusion: The applicability of the proposed platform would extend beyond the reported approach, where glycylglycine, low inducer concentration and post-induction temperature, combined with the moderately-strong constitutive promoter enables the stable production of soluble/active proteins, even those with reported toxicity. Also, the newly developed immunoassay provides a cost-effective point-of-care diagnostic tool for active HCV viremia that could be useful in resource-limited settings.

15 November 2024 in Virology Journal
Verified
Journal Article
Open access
PDF file
REReem El-Shenawy
Reem El-Shenawy
RMRehab I. Moustafa
Rehab I. Moustafa
NHNaiera M. Helmy
Naiera M. Helmy
YEYasmine S. El-Abd
Yasmine S. El-Abd
Ashraf TabllAshraf Tabll
Ashraf Tabll
Heba ShawkyHeba Shawky
Heba Shawky
Background: Although direct-acting antivirals (DAAs) have revolutionized the management of chronic HCV, the debatable association with hepatocellular carcinoma (HCC) occurrence/recurrence has raised major concerns about their long-term use, especially in cirrhotic cases. The role of epithelial tight junction proteins (TJPs) in hepatocarcinogenesis has been highlighted; however, the association of their expression in peripheral blood mononuclear cells (PBMCs) with HCC has rarely been reported. This study aimed to explore the role of peripheral claudin (Cldn)1 in liver pathogenesis and its crosstalk with soluble immune mediators in HCC prognosis. Methods: The study population included six independent subgroups: healthy controls, cirrhotic/non-cirrhotic treatment-naïve HCV patients, DAA-SVR patients, and anticancer treatment-naïve de novo HCC patients. The laboratory tests included serum levels of alpha-fetoprotein (AFP), albumin, liver transaminases, total bilirubin, and CBC profiling. The serum levels of soluble cluster of differentiation (sCD)163, IL-10, and IL-12 were estimated by corresponding ELISA kits, whereas the levels of Cldn1 and transforming growth factor (TGF)-β in PBMCs were quantified using quantitative PCR (qPCR). Results: Serum sCD163, IL-10, and IL-12 levels were significantly higher in the HCC patient group than in the control and non-malignant patient groups (P < 0.0001). No significant difference was detected in the serum levels of the three markers between cirrhotic and non-cirrhotic patients of chronic HCV, whereas their levels were significantly different between cirrhotic and non-cirrhotic SVRs (P < 0.0001). Similarly, the transcriptional levels of peripheral Cldn1 and TGF-β were significantly higher in patients with HCC and non-malignant cirrhosis than in patients without cirrhosis (P = 0.0185–<0.0001 and 0.0089–<0.0001, respectively). Logistic regression analysis revealed a significant association between all the abovementioned markers and HCC (P = 0.0303 to < 0.0001), which was further confirmed by the results of receiver operating characteristic (ROC) analysis, which revealed an area under the curve (AUC) value ranging from 0.883 to 0.996. The calculated cutoff values demonstrated remarkable prognostic capacity, with ranges of 88–99.41% and 82.14–97.92% and positive/negative predictive values ranging from 84.62 to 98.3% and 92–98%, respectively. Conclusion: Serum sCD163, IL-10, IL-12 and peripheral Cldn1 and TGF-β expression levels represent novel non-invasive HCC biomarkers that maintain their predictive power under different pathological conditions and circumvent the drawbacks of conventional prognostic markers in patients with mild cirrhosis and/or normal AFP, albumin, and/or platelet counts.

10 November 2025 in Archives of Virology
Verified
Journal Article
Closed access
PDF file
NHNahla Hussein
Nahla Hussein
RARasha A. M. Azouz
Rasha A. M. Azouz
REReem El-Shenawy
Reem El-Shenawy
NHNaiera M. Helmy
Naiera M. Helmy
Ashraf TabllAshraf Tabll
Ashraf Tabll
AAAhmed Attia Ali
Ahmed Attia Ali